Cell Biotech Reports 36.7 Billion KRW in Cumulative Q3 Sales... Strong Export Performance of 'Duolac'

[Asia Economy Reporter Lee Gwan-joo] Microbiome specialist company Cell Biotech announced on the 8th that it recorded provisional results of 36.7 billion KRW in cumulative sales, 4.6 billion KRW in operating profit, and 11.7 billion KRW in net profit for the third quarter of this year.

Compared to the same period last year, sales increased by 5.4%, while operating profit decreased by 8.1%. Net profit grew by 57.1%.

Export growth drove the performance. Exports in the third quarter increased by 26% year-on-year due to improvements in exports to Europe and Southeast Asia. In particular, the 100% Korean premium probiotic brand 'Duolac,' developed in-house, grew by 22% in overseas markets.

A Cell Biotech official said, "We will strive to achieve results in developing new products that consumers need and microbiome new drugs by utilizing the research and development technology accumulated through the probiotics business."

The 'Korean probiotics' developed by Cell Biotech are exported to more than 40 countries worldwide, including Denmark, the pioneer country of probiotics, with excellent quality, and have ranked first in domestic probiotics exports for nine consecutive years.

This content was produced with the assistance of AI translation services.